• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Candel Therapeutics Inc (NQ: CADL )

    8.850 -0.170 (-1.88%)
    Streaming Delayed Price Updated: 12:50 PM EDT, May 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,478,150
    Open 9.330
    Bid (Size) 8.850 (6)
    Ask (Size) 8.930 (1)
    Prev. Close 9.020
    Today's Range 8.430 - 10.86
    52wk Range 0.6600 - 11.40
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
    From Candel Therapeutics
    Via GlobeNewswire
    How Is The Market Feeling About Candel Therapeutics?
    Via Benzinga

    Performance

    YTD
    +510.34%
    +510.34%
    1 Month
    +33.28%
    +33.28%
    3 Month
    +570.45%
    +570.45%
    6 Month
    +851.61%
    +851.61%
    1 Year
    +439.63%
    +439.63%

    More News

    Read More
    Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    What's Going On With Candel Therapeutics Stock?
    Via Benzinga
    Exposures Product Safety
    Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
    From Candel Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
    From Candel Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    What's Going On With Candel Therapeutics Stock On Friday?
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Unusually High Volume Points to Upside in These Stocks
    Via MarketBeat
    Topics ETFs
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    Ford, Candel Therapeutics, Nvidia, Palantir, Tesla: Why These 5 Stocks Are On Investors' Radars Today
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
    From Candel Therapeutics
    Via GlobeNewswire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Via InvestorPlace
    Micro-Cap Cancer Focused Candel Therapeutics Highlights Encouraging Data From Brain Tumor Immunotherapy
    Via Benzinga
    Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
    From Candel Therapeutics
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.